Institut Jean Godinot

Recent papers from Institut Jean Godinot

1. The impact of chemotherapy-induced menopause on quality of life 30 months following treatment among young women with non-metastatic breast cancer: results from the prospective multicentre MENOCOR clinical trialHealth and Quality of Life Outcomes · 2026
2. Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trialThe Lancet · 2025
3. Checkpoint inhibitors and chronic comedications: A retrospective study on immune-related adverse eventsJournal of Oncology Pharmacy Practice · 2026
4. Research Study Attrition and Participant-Informed Retention Strategies Among Cancer SurvivorsJAMA Network Open · 2026
5. Cerebral small vessel disease burden in late-onset epilepsy of unknown aetiology: insights from a prospective multicenter cohortSeizure · 2026
6. Ivonescimab in combination with chemotherapy in advanced or metastatic gastric cancer (GC) or esophagogastric junction cancer (EGJC): The UCGI 52 – GRACIE trialDigestive and Liver Disease · 2026
7. Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohortESMO Open · 2026
8. 27O Long-term survival outcomes and immune subgroup analyses in the COLIBRI study: Induction nivolumab plus ipilimumab with immunotherapy maintenance (ICB) prior to and following chemoradiation (RT-CT) in locally advanced cervical cancer (LACC)ESMO Open · 2026
9. 144P Mapping of clinically relevant antibody-drug conjugates targets by RNA sequencing in primary inoperable high-grade serous ovarian carcinoma before and after NACT in the NeoPembrOV/GINECO trialESMO Open · 2026
10. Base of tongue volume and dose as predictors of late dysphagia after definitive or adjuvant radiotherapy for oral cavity squamous cell carcinomaPhysics and Imaging in Radiation Oncology · 2026
11. Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG networkGynecologic Oncology · 2026
12. Cell-free DNA dynamics and progression-free survival in metastatic gastroesophageal adenocarcinoma: insights from the REGIRI-PRODIGE 58 ancillary studynpj Precision Oncology · 2026
13. Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspectiveCancer Treatment Reviews · 2026
14. Colorectal cancer screening participation in childhood cancer survivors: a report from the French Childhood Cancer Survivors Study (FCCSS)International Journal of Epidemiology · 2026
15. Evaluating Advanced Practice Nursing Implementation and Activity Indicators in Oncology and Haemato‐OncologyJournal of Clinical Nursing · 2026
16. Breast Cancer Diagnosis and HER2+ Versus Triple Negative Discrimination by Infrared Spectral HistopathologyAnalytical Chemistry · 2026
17. Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohortBreast Cancer Research · 2026
18. Safety of concurrent T-DM1 and radiation therapy in HER2-positive breast cancer with residual disease after neoadjuvant chemotherapyInternational Journal of Radiation Biology · 2026
19. Defining physician acceptance of radiosensitivity testing for guiding therapeutic interventions in head and neck cancer: A Delphi consensus studyClinical and Translational Radiation Oncology · 2026
20. Phase II study evaluating ivonescimab in combination with chemotherapy as first- and second-line treatment of advanced or metastatic gastric and gastroesophageal adenocarcinoma patients (UCGI 52 – GRACIE).Journal of Clinical Oncology · 2026